Browse our anti-Kallikrein 7 (KLK7) Antibodies

Mouse (Murine) Kallikrein 7 (KLK7) interaction partners

1. KLK7 is an important enzyme in the degradation and clearance of deposited Amyloid beta species by astrocytes involved in the pathogenesis of Alzheimer's disease.

2. A previously unrecognized role of KLK7 in adipose tissue with effects on whole body energy expenditure and insulin sensitivity.

3. Ablation of KLK7 is not sufficient to rescue the lethal effect of LEKTI-deficiency. Double deficiency of both KLK7 and KLK5 completely rescues Netherton Syndrome-like phenotype.

4. Higher hK7 expression is associated with cervical adenocarcinomas

5. Prolonged Klk7 neutralization provokes profound abnormalities in Klk7 function, due to pH-induced high serine protease activity that degrades lipid processing enzymes and corneodesmosomes proteins.

Human Kallikrein 7 (KLK7) interaction partners

1. Structures of BbKI complexed with the catalytic domain of human plasma kallikrein were modeled, as well as those with KLK4 and KLK7, and the structures were analyzed in order to identify the interactions that are responsible for inhibitory potency.

2. results demonstrate that aberrant KLK7 expression leads to a switch to a more malignant phenotype suggesting a potential role of KLK7 in melanoma invasion; KLK7 may represent a biomarker for melanoma progression and may be a potential therapeutic target for melanoma

3. he expression level of KLK7 in pancreatic ductal adenocarcinoma was higher than that in paired adjacent tissues and it is an independent risk factor for vascular invasion of pancreatic cancer.

4. These results show that aberrant KLK7 expression leads to a switch from proliferative to invasive phenotype, suggesting a potential role of KLK7 in melanoma progression.

5. KLK7 is differentially expressed in lesional biopsy specimens from patients with atopic eczema relative to normal skin

6. impaired KLK7 secretion from lamellar granules and increased LEKTI expression could underlie the insufficient activation of KLK in atopic dermatitis.

7. Epigenetic regulation of KLK7 gene expression in pancreatic and cervical cancer cells

8. Korean X-linked ichthyosis patients exhibited unimpaired skin barrier function and frequent association with the KLK7 gene polymorphism, which may differentiate them from Western X-linked ichthyosis patients.

9. This report demonstrates that concurrent loss of KLK5 and KLK7 associates with a poor clinical outcome in Squamous-Cell Carcinoma and could therefore serve as prognostic marker in this disease.

10. Data demonstrate that elevated levels of KLK6, KLK7 and KLK9 proteins are associated with poor glioblastoma patients survival.

11. Our findings suggest that serum KLK7 may be a valuable diagnostic biomarker for cervical cancer, and may help to determine the individual prognosis of these patients.

12. KLK6 and KLK7 mRNA and protein overexpression is directly associated with early-stage ovarian tumors.

13. Proteolytic cleavage of midkine, CYR61, and tenascin-C govern the pathophysiological roles of KLK7.

14. Early-stage oral squamous cell carcinoma and high KLK7 mRNA levels were correlated with the rs10581213(wt/ins + ins/ins) genotypes

15. These results demonstrate the aberrant expression of KLK7 in colon cancer cells and tissues and its involvement in cell proliferation in vitro and in vivo.

16. Daata indicate that the peptide Abz-NLY( downward arrow)RVE-Q-EDDnp is the best synthetic substrate for Kallikrein-related peptidase 7 (KLK7) [kcat/Km=455 (mMs)(-1)].

17. KLK7 and KLK14 gene expression can be regarded as markers of poor prognosis for colorectal cancer patients with discriminating power between CC and adenoma patients.

18. Prochemerin processing protease converts prochemerin into active chemerinF; the activating truncation by the protease may trigger a structural C-terminal rearrangement leading to increased affinity of chemerin to chemokine-like receptor (CMKLR)1.

19. High KLK7 expression is associated with pancreatic ductal adenocarcinoma.

20. regulation of procaspase-14 maturation during terminal differentiation is a unique two-step process involving KLK7 and an activation intermediate of caspase-14.